Paxlovid for Long COVID: Trial Finds No Symptom Benefit

What did the Paxlovid trial find for Long COVID?

RECOVER-VITAL was a randomized, double-blind phase 2 trial conducted at 69 U.S. sites. Researchers assigned 964 adults to treatment groups; 959 were included in the main analysis. Participants had persistent symptoms for at least 12 weeks, involving difficulty thinking clearly, problems regulating heart rate or blood pressure, or symptoms associated with exertion. The main assessment measured meaningful changes in patient-reported symptoms at day 90. [RECOVER-VITAL publication](https://recovercovid.org/publications/nirmatrelvir-ritonavir-targeting-viral-persistence-post-covid-19-condition-long-covid).

Participants received nirmatrelvir–ritonavir, marketed as Paxlovid, for either 25 days or 15 days followed by 10 days of ritonavir plus placebo. The comparison group received ritonavir plus placebo throughout. Neither active regimen outperformed the comparison treatment on the primary outcomes. NIH reported that symptoms improved at similar rates across the groups during follow-up, illustrating why improvement after taking a medicine alone cannot establish that the medicine caused it. [NIH research summary](https://www.nih.gov/news-events/nih-research-matters/antiviral-drug-did-not-improve-long-covid-symptoms).

Why did researchers test an antiviral for persistent symptoms?

One proposed explanation for Long COVID is that the virus persists in some people after their acute illness. Paxlovid offered a way to investigate that possibility. Nirmatrelvir blocks a viral enzyme needed for replication; ritonavir slows nirmatrelvir's breakdown, helping maintain effective drug concentrations. However, a medicine's antiviral mechanism does not establish that it will relieve a chronic condition after infection. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s010lbl.pdf).

The appropriate interpretation is limited to the treatment and population studied: these courses did not demonstrate symptom benefit. The result cannot, by itself, establish whether persistent virus contributes to Long COVID or whether another intervention could work. NIH says researchers are analyzing blood samples to investigate viral persistence and treatment response. Those analyses may help refine future hypotheses, but they do not currently identify a subgroup proven to benefit from extended Paxlovid. [NIH research summary](https://www.nih.gov/news-events/nih-research-matters/antiviral-drug-did-not-improve-long-covid-symptoms).

What do these results mean for Long COVID treatment?

Paxlovid's FDA-approved adult indication is acute mild-to-moderate COVID-19 in people at high risk of severe illness. Its standard course lasts five days and begins within five days of symptom onset. That clinical purpose differs from treating persistent symptoms months later. Prescribing also requires a medication review because ritonavir can cause serious interactions; kidney function affects dosing. Patients should discuss treatment changes with their prescriber rather than extending a course themselves. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s010lbl.pdf).

CDC recommends tailoring Long COVID management to the symptoms that most affect a person's life, alongside treatment of underlying conditions. Rehabilitation requires attention to post-exertional malaise, when even modest physical or mental activity can trigger delayed symptom worsening. A symptom and activity diary can help guide discussions about tolerable activity and support needs. The trial's negative result leaves an unmet treatment need; it does not remove the need for ongoing assessment and care. [CDC clinical guidance](https://www.cdc.gov/long-covid/hcp/clinical-guidance/index.html).